Massachusetts Society of Clinical Oncologists - FDA approves atezolizumab (Tecentriq) for BRAF V600 unresectable or metastatic melanoma

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA approves atezolizumab (Tecentriq) for BRAF V600 unresectable or metastatic melanoma

FDA approves atezolizumab (Tecentriq) for BRAF V600 unresectable or metastatic melanoma

03 Aug 2020 7:18 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org